ECHDC3 and acute myeloid leukemia: In the present study, the expression of ECHDC3 could divide int-risk AML and FLT3+NPM1+AML into two subgroups with distinct survival rates, which might improve the prediction of the survival and guide post-remission treatment in int-risk AML.